Predict your next investment

PROOF company logo
Venture Capital
FINANCIAL | Investment Firms & Funds
proof.vc

See what CB Insights has to offer

Investments

5

Funds

27

About PROOF

PROOF is an investment fund from noted local VCs John Backus, John Burke and Thanasis Delistathis.

PROOF Headquarter Location

11911 Freedom Drive Suite 1080

Reston, Virginia, 20190,

United States

571-969-4926

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

PROOF Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PROOF Rank

Latest PROOF News

Saillant Therapeutics Reports Proof Of Concept Of Its Treatment In Heart Failure Showing Functional Reversal And Myocardial Rejuvenation

Nov 4, 2020

Saillant Therapeutics Reports Proof Of Concept Of Its Treatment In Heart Failure Showing Functional Reversal And Myocardial Rejuvenation NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ --  Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead... Author: Nov 4, 2020 4:23 AM EST NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ --  Saillant Therapeutics , an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which it induced a clear reversal to normal of the functional impairments in heart failure, such as Cardiac Output and Ejection Fraction. Moreover, histological reversal demonstrated an unprecedented rejuvenation of myocardial tissue. These results, with its lead compound, will allow the company to start clinical trials within one to two years. Preclinical safety studies are presently being conducted in collaboration with renowned CROs. Heart failure The company's original science was based on a novel therapy for heart failure. Using a heart failure animal model, Saillant found out that the new treatment restored heart function in failing hearts after four weeks of treatment. Treated hearts reversed to normal geometry with a significant reduction in scar tissue (fibrosis). Once heart cells are under stress, there is only a limited period during which they can overcome this stress. If that fails, cell death occurs. The lead compound (ST02) allows the anti-stress response to remain active for a longer time period, allowing resolvment of the stress and thus preventing cell death. This protection allows maintenance of tissue integrity and function of the failing heart. Virus inhibiting therapy ending virus replication While many parties worldwide are focused on developing vaccines and therapies based on antibodies, Saillant targets the complete elimination of viruses, including Covid-19, which presages the outbreak of most upcoming virus variants. Recently Saillant discovered promising novel mechanisms that could lead to the development of several novel anti-viral therapies. These mechanisms are based on the activation of a specific cellular master regulator. Compounds acting through these mechanisms induce adaptive functions in infected cells, thereby inhibiting virus replication. Future activities Saillant will continue  testing the effect of its lead compound in different heart failure models including myocardial infarction and diabetic cardiomyopathy. In addition, Saillant has teamed up with several partners to test its lead compound in disease models that share the same mechanisms of pathology such as Alzheimer's disease and COVID-19 infection. Joost van Bree, CEO of Saillant Therapeutics, states: "I am very excited that we have discovered a novel mechanism of action for the treatment of heart failure. Heart failure is an indication of a high unmet medical need, as it affects more than 30 million patients globally. Half of these patients will succumb to this disease within 5 years after diagnosis. Moreover, due to the frequent need for hospitalization, heart failure causes over 95 billion USD in annual global health care costs." "Unlike current drug therapies that provide only moderate symptomatic relief, our lead compound offers a genuinely novel and innovative perspective, as it is unique in its disease-modifying effect, restoring myocardial functionality. We will now vigorously pursue the development program for establishing the necessary data package to get IND approval towards initial clinical trials in the target patient population. "  About Saillant Therapeutics Saillant Therapeutics, established in 2018 by Dr. Hamid el Azzouzi and Dr. Ad van Gorp, and recently joined by Dr. Joost van Bree as CEO, leverages its expertise in preclinical drug development to further validate and develop the promising therapeutic strategy of its "ST"- platform against acute ischemic stroke, heart failure (HF), Alzheimer's disease and viral infections in general. The "ST" lead  compounds activate a cellular master regulator, thus controlling adaptive functions in various cells and tissues. Therapeutic intervention through this regulator mechanism enables the prevention of tissue damage to vital organ systems such as the cardiovascular system and the central nervous system. The same mechanism also effectively inhibits intracellular virus replication. Saillant Therapeutics has a product pipeline covering novel compounds of which a number of therapeutic leads were selected. To date, seed financing has enabled the preclinical development and validation of these "ST" derivatives. It is the ambition of Saillant to advance its "ST" platform also towards a variety of applications, resulting in at least one lead drug candidate reaching the clinic before the end of 2022. For more information, please visit www.saillanttherapeutics.nl Forward-looking Statements This press release of Saillant Therapeutics BV and its subsidiaries ("Saillant," the "Company" or the "Group") may contain forward-looking statements including without limitation those regarding Saillant's financial projections, market expectations, developments, partnerships, plans, strategies, and capital expenditures. The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation the effect of competitive, political and economic factors, legal claims, the Company's ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices, and the Company's ability to identify, develop and successfully commercialize new products, markets or technologies. As a result, the Company's actual performance, position, and financial results and statements may differ materially from the plans, goals, and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue unless required by laws or regulations. Contacts                  LifeSpring LifeSciences Communication, Amsterdam, The NetherlandsLeon MelensT: +31-6-538-16-427E: lmelens@lifespring.nl View original content to download multimedia: http://www.prnewswire.com/news-releases/saillant-therapeutics-reports-proof-of-concept-of-its-treatment-in-heart-failure-showing-functional-reversal-and-myocardial-rejuvenation-301166230.html SOURCE Saillant Therapeutics

PROOF Investments

5 Investments

PROOF has made 5 investments. Their latest investment was in ForMotiv as part of their Series A on September 9, 2021.

CBI Logo

PROOF Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/13/2021

Series A

ForMotiv

$6M

Yes

3

5/23/2019

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

4/17/2019

Series B - IV

Subscribe to see more

$99M

Subscribe to see more

10

8/29/2017

Series D

Subscribe to see more

$99M

Subscribe to see more

10

12/1/2016

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/13/2021

5/23/2019

4/17/2019

8/29/2017

12/1/2016

Round

Series A

Series B - II

Series B - IV

Series D

Unattributed VC

Company

ForMotiv

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$6M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

10

PROOF Fund History

27 Fund Histories

PROOF has 27 funds, including PROOF Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/29/2020

PROOF Fund II

$109.63M

7

12/28/2020

PROOF Side II

$10.37M

6

12/21/2020

Wonder Arcadia

$2M

1

11/17/2020

Javelin PROOF II C3

Subscribe to see more

$99M

10

10/15/2020

Javelin PROOF II C2

Subscribe to see more

$99M

10

Closing Date

12/29/2020

12/28/2020

12/21/2020

11/17/2020

10/15/2020

Fund

PROOF Fund II

PROOF Side II

Wonder Arcadia

Javelin PROOF II C3

Javelin PROOF II C2

Fund Type

Subscribe to see more

Subscribe to see more

Status

Amount

$109.63M

$10.37M

$2M

$99M

$99M

Sources

7

6

1

10

10

PROOF Team

2 Team Members

PROOF has 2 team members, including undefined undefined, undefined.

Name

Work History

Title

Status

John Backus

Founder

Current

Thanasis Delistathis

Founder

Current

Name

John Backus

Thanasis Delistathis

Work History

Title

Founder

Founder

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.